Year: 2025

Company reports Diluted EPS of $6.87, Economic EPS of $6.10 in the third quarter of 2025Net client cash inflows of approximately $9 billion in the third quarter and approximately $17 billion in the year to date, driven by ongoing momentum in alternative strategies Net Income (controlling interest) of $212 million includes gain of approximately $100 million on Peppertree transaction(i) Economic Earnings per share of $6.10 in the third quarter, reflecting growth of 27% relative to the prior-year quarter Strategic collaboration with BBH enhances AMG’s position as a leading sponsor of alternative strategies for U.S. wealth marketplace Share repurchases of approximately $350 million in the year to date, including approximately $77 million in the third quarterWEST PALM BEACH, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) — AMG, a strategic...

Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continues Achieved profitability in the first full quarter of YUTREPIA sales More than 2,000 unique patient prescriptions and 1,500 patient starts to date Company to host webcast today at 8:30 a.m. ETMORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third quarter ended September 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on November 3, 2025, to review financial performance and provide a corporate update. Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “Our third quarter results...

Net Sales Growth of 14% Outperforms CategoryCompany Achieves Positive Free Cash Flow in Third Quarter and Now Expects to be Free Cash Flow Positive in 2025Updates 2025 Guidance BEDMINSTER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) — Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its third quarter and nine months ended September 30, 2025. Third Quarter 2025 Financial Highlights Compared to Prior Year PeriodNet sales of $288.8 million, an increase of 14.0%. Gross margin of 39.5%, compared to the prior year period of 40.4%. Adjusted Gross Margin of 46.0%, compared to the prior year period of 46.5%.1 Net income of $101.7 million, including a discrete $77.9 million tax benefit as a result of sustained profitability, compared to the prior year period net income of $11.9 million. Adjusted...

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stages Demonstrated encouraging anti-tumor activity and manageable safety profile of pumitamig (BNT327/BMS986545), a bispecific antibody candidate targeting PD-L11 and VEGF-A, in first disclosed interim data from global Phase 2 trial in extensive-stage small cell lung cancer  Plan to initiate additional pivotal trials for pumitamig in first-line microsatellite stable colorectal cancer and first-line gastric cancer Launched variant-adapted COVID-19 vaccine for the 2025/2026 vaccination season in multiple regions Third quarter 2025 revenues of €1.5 billion2, net loss of €28.7 million and basic and diluted loss per share of €0.12 ($0.143) Strengthened financial...

Net income attributable to common shareholders increased by 35.1% to JPY846.8 million, or $5.9 millionTOKYO, Nov. 03, 2025 (GLOBE NEWSWIRE) — Lead Real Estate Co., Ltd (Nasdaq: LRE) (“LRE” or the “Company”), a Japanese real estate developer of luxury residential properties, including single-family homes and condominiums across Tokyo, Kanagawa prefecture and Sapporo, and which develops and operates the ENT TERRACE brand of extended-stay hotels, today announced financial results for the fiscal year ended June 30, 2025. Total revenue was JPY18.8 billion ($130.7 million) for the fiscal year ended June 30, 2025, compared to JPY19.0 billion for the fiscal year ended June 30, 2024, a decrease of 0.6%. The primary revenue component, real estate sales, was JPY18.3 billion ($127 million), compared to JPY18.5 billion...